Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

dostęp otwarty

Tom 8, Nr 2 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2022-03-02
Pokaż PDF Pokaż HTML
Pobierz cytowanie

Wytyczne postępowania diagnostyczno-terapeutycznego w raku wątrobowokomórkowym

Maciej Krzakowski1, Jarosław Reguła2, Halina Cichoż-Lach3, Andrzej Cieszanowski45, Barbara Górnicka6, Michał Grąt7, Marek Hartleb8, Krzysztof Korzeniowski5, Tomasz Kubiatowski9, Joanna Podgórska45, Piotr Potemski10, Grzegorz Rosiak5, Tomasz Stokłosa6, Benedykt Szczepankiewicz6, Michał P. Wasilewicz11, Tadeusz Wróblewski7, Piotr Wysocki12, Krzysztof Zieniewicz7
Onkol Prakt Klin Edu 2022;8(2):81-124.
Afiliacje
  1. Klinika Nowotworów Płuca i Klatki Piersiowej, Narodowy Instytut Onkologii im. M. Skłodowskiej-Curie — Państwowy Instytut Badawczy w Warszawie
  2. Klinika Gastroenterologii Onkologicznej, Narodowy Instytut Onkologii im. Marii Skłodowskiej‑Curie – Państwowy Instytut Badawczy; Klinika Gastroenterologii, Hepatologii i Onkologii Klinicznej CMKP, Warszawa
  3. Klinika Gastroenterologii z pracownią Endoskopową, Uniwersytet Medyczny w Lublinie
  4. Zakład Radiologii 1, Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy w Warszawie
  5. Drugi Zakład Radiologii Klinicznej, Uniwersyteckie Centrum Kliniczne, Warszawski Uniwersytet Medyczny
  6. Katedra Patomorfologii, Warszawski Uniwersytet Medyczny
  7. Klinika Chirurgii Ogólnej, Transplantacyjnej i Wątroby, Warszawski Uniwersytet Medyczny
  8. Klinika Gastroenterologii i Hepatologii, Śląski Uniwersytet Medyczny w Katowicach
  9. Klinika Onkologii i Immunoonkologii z Oddziałem Dziennym Terapii Onkologicznej, Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie
  10. Klinika Chemioterapii Nowotworów Uniwersytetu Medycznego w Łodzi, Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Łodzi
  11. Katedra i Klinika Gastroenterologii Pomorskiego Uniwersytetu Medycznego; Przykliniczna Poradnia Transplantologiczna, Samodzielny Publiczny Szpital Kliniczny Nr 1 PUM, Szczecin
  12. Katedra i Klinika Onkologii, Uniwersytet Jagielloński — Collegium Medicum w Krakowie

dostęp otwarty

Tom 8, Nr 2 (2022)
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2022-03-02

Streszczenie

Rak wątrobowokomórkowy jest najczęstszym pierwotnym nowotworem wątroby. Częstość występowania raka wątrobowokomórkowego zwiększała się na świecie w ciągu ostatnich dekad. W Polsce rak wątrobowo komórkowy jest rozpoznawany u około 1500 chorych rocznie. Rokowanie chorych na raka wątrobowokomórkowego jest nadal niezadowalające. Chorobie można zapobiegać w znacznym stopniu przez skuteczniejszą kontrolę czynników ryzyka oraz nadzór nad osobami z marskością wątroby. Właściwe postępowanie diagnostyczne i terapeutyczne może poprawić rokowanie chorych na raka wątrobowokomórkowego. Przedstawiamy aktualizowaną wersję wytycznych postępowania u osob z czynnikami ryzyka oraz rozpoznaniem raka wątrobowokomórkowego. Opracowanie zostało przygotowane przez przedstawicieli wszystkich specjalności medycznych zaangażowanych w postępowaniu u chorych na raka wątrobowokomórkowego.

Streszczenie

Rak wątrobowokomórkowy jest najczęstszym pierwotnym nowotworem wątroby. Częstość występowania raka wątrobowokomórkowego zwiększała się na świecie w ciągu ostatnich dekad. W Polsce rak wątrobowo komórkowy jest rozpoznawany u około 1500 chorych rocznie. Rokowanie chorych na raka wątrobowokomórkowego jest nadal niezadowalające. Chorobie można zapobiegać w znacznym stopniu przez skuteczniejszą kontrolę czynników ryzyka oraz nadzór nad osobami z marskością wątroby. Właściwe postępowanie diagnostyczne i terapeutyczne może poprawić rokowanie chorych na raka wątrobowokomórkowego. Przedstawiamy aktualizowaną wersję wytycznych postępowania u osob z czynnikami ryzyka oraz rozpoznaniem raka wątrobowokomórkowego. Opracowanie zostało przygotowane przez przedstawicieli wszystkich specjalności medycznych zaangażowanych w postępowaniu u chorych na raka wątrobowokomórkowego.

Pełny tekst:

Pokaż PDF Pokaż HTML
Pobierz cytowanie

Słowa kluczowe

rak wątrobowokomórkowy; zapobieganie; rozpoznawanie; leczenie

Informacje o artykule
Tytuł

Wytyczne postępowania diagnostyczno-terapeutycznego w raku wątrobowokomórkowym

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 8, Nr 2 (2022)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

81-124

Opublikowany online

2022-03-02

Wyświetlenia strony

2360

Wyświetlenia/pobrania artykułu

697

Rekord bibliograficzny

Onkol Prakt Klin Edu 2022;8(2):81-124.

Słowa kluczowe

rak wątrobowokomórkowy
zapobieganie
rozpoznawanie
leczenie

Autorzy

Maciej Krzakowski
Jarosław Reguła
Halina Cichoż-Lach
Andrzej Cieszanowski
Barbara Górnicka
Michał Grąt
Marek Hartleb
Krzysztof Korzeniowski
Tomasz Kubiatowski
Joanna Podgórska
Piotr Potemski
Grzegorz Rosiak
Tomasz Stokłosa
Benedykt Szczepankiewicz
Michał P. Wasilewicz
Tadeusz Wróblewski
Piotr Wysocki
Krzysztof Zieniewicz

Referencje (278)
  1. Akinyemiju T, Abera S, Ahmed M, et al. Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017; 3(12): 1683–1691.
    CrossRefPubMed
  2. Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020; 147(2): 317–330.
    CrossRefPubMed
  3. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1): 182–236.
    CrossRefPubMed
  4. Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016; 2: 16018.
    CrossRefPubMed
  5. Villanueva A. Hepatocellular Carcinoma. N Engl J Med. 2019; 380(15): 1450–1462.
    CrossRefPubMed
  6. International Agency for Research on Cancer. GLOBOCAN 2018. IARC. https://gco.iarc.fr/today/online-analysis-map?v=2020&mode=population&mode_population=continents&population=900&populations=900&key=asr&sex=0&cancer=11&type=0&statistic=5&prevalence=0&population_groupearth&color_palette=default&map_scale=quantile&map_nb_colors=5&continent=0&rotate=%255B10%252C0%255D.
  7. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424.
    CrossRefPubMed
  8. McGlynn KA, Petrick JE, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021; 73: S1.
  9. Valery PC, Laversanne M, Clark PJ, et al. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology. 2018; 67(2): 600–611.
    CrossRefPubMed
  10. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015; 19(2): 223–238.
    CrossRefPubMed
  11. Fact Sheets by Population-Globocan-IARC n.d. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (18.12.2017).
  12. Bosetti C, Levi F, Boffetta P, et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology. 2008; 48(1): 137–145.
    CrossRefPubMed
  13. Welzel TM, Graubard BI, Quraishi S, et al. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013; 108(8): 1314–1321.
    CrossRefPubMed
  14. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014; 60(5): 1767–1775.
    CrossRefPubMed
  15. Tanaka H, Imai Y, Hiramatsu N, et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med. 2008; 148(11): 820–826.
    CrossRefPubMed
  16. Qiu D, Katanoda K, Marugame T, et al. A Joinpoint regression analysis of long-term trends in cancer mortality in Japan (1958-2004). Int J Cancer. 2009; 124(2): 443–448.
    CrossRefPubMed
  17. Golabi P, Fazel S, Otgonsuren M, et al. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore). 2017; 96(9): e5904.
    CrossRefPubMed
  18. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1): 6.
    CrossRefPubMed
  19. Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014; 74(11): 2913–2921.
    CrossRefPubMed
  20. Chang MH, You SL, Chen CJ, et al. Taiwan Hepatoma Study Group. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009; 101(19): 1348–1355.
    CrossRefPubMed
  21. Chang MH, You SL, Chen CJ, et al. Taiwan Hepatoma Study Group. Long-term Effects of Hepatitis B Immunization of Infants in Preventing Liver Cancer. Gastroenterology. 2016; 151(3): 472–480.e1.
    CrossRefPubMed
  22. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012; 142(6): 1264–1273.e1.
    CrossRefPubMed
  23. White DL, Thrift AP, Kanwal F, et al. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017; 152(4): 812–820.e5.
    CrossRefPubMed
  24. Yang JuD, Mohamed EA, Aziz AO, et al. Africa Network for Gastrointestinal and Liver Diseases. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017; 2(2): 103–111.
    CrossRefPubMed
  25. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2018 Sub (1975-2016) - Linked To County Attributes - Total U.S., 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2019, based on the November 2018 submission; 2019.
  26. Ioannou GN, Splan MF, Weiss NS, et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2007; 5(8): 938–45, 945.e1.
    CrossRefPubMed
  27. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2018; 68(2): 723–750.
    CrossRefPubMed
  28. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol consumption and their interaction in the causation of hepatocellular carcinoma. Int J Cancer. 2000; 85(4): 498–502.
    PubMed
  29. Ioannou GN, Bryson CL, Weiss NS, et al. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology. 2013; 57(1): 249–257.
    CrossRefPubMed
  30. Raimondi S, Bruno S, Mondelli MU, et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol. 2009; 50(6): 1142–1154.
    CrossRefPubMed
  31. Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014; 60(1): 98–105.
    CrossRefPubMed
  32. Schlesinger S, Aleksandrova K, Pischon T, et al. Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort. Ann Oncol. 2013; 24(9): 2449–2455.
    CrossRef
  33. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ. 2015; 350: g7607.
    CrossRefPubMed
  34. Yu MW, Lin CL, Liu CJ, et al. Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study. Gastroenterology. 2017; 153(4): 1006–1017.e5.
    CrossRefPubMed
  35. EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016; 64(6): 1388–1402.
    CrossRef
  36. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010; 51(6): 1972–1978.
    CrossRefPubMed
  37. Perumpail RB, Wong RJ, Ahmed A, et al. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience. Dig Dis Sci. 2015; 60(10): 3142–3148.
    CrossRefPubMed
  38. Kawamura Y, Arase Y, Ikeda K, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol. 2012; 107(2): 253–261.
    CrossRefPubMed
  39. Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24(3): 1073274817729245.
    CrossRefPubMed
  40. Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular carcinoma. Gastroenterology. 2004; 127(5 Suppl 1): S87–S96.
    CrossRefPubMed
  41. Deugnier YM, Guyader D, Crantock L, et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology. 1993; 104(1): 228–234.
    CrossRefPubMed
  42. Post G, Shalev N, Baumgarten A, et al. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017; 67(2): 370–398.
    CrossRefPubMed
  43. Tseng CH, Tseng CM, Wu JL, et al. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. J Gastroenterol Hepatol. 2020; 35(10): 1684–1693.
    CrossRefPubMed
  44. Gu L, Yao Q, Shen Z, et al. Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta-analysis. J Gastroenterol Hepatol. 2020; 35(9): 1467–1476.
    CrossRefPubMed
  45. Li M, Lv T, Wu S, et al. Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis. Hepatol Int. 2020; 14(1): 105–114.
    CrossRefPubMed
  46. Ma L, Liu J, Wang W, et al. Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients. Future Oncol. 2020; 16(11): 675–686.
    CrossRefPubMed
  47. Colombo M, Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol. 2014; 28(5): 771–781.
    CrossRefPubMed
  48. D'Ambrosio R, Della Corte C, Colombo M. Hepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C Therapy. Int J Mol Sci. 2015; 16(8): 19698–19712.
    CrossRefPubMed
  49. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016; 65(4): 719–726.
    CrossRefPubMed
  50. Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016; 65(4): 727–733.
    CrossRefPubMed
  51. Waziry R, Hajarizadeh B, Grebely J, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017; 67(6): 1204–1212.
    CrossRefPubMed
  52. Inoue M, Yoshimi I, Sobue T, et al. JPHC Study Group. Influence of coffee drinking on subsequent risk of hepatocellular carcinoma: a prospective study in Japan. J Natl Cancer Inst. 2005; 97(4): 293–300.
    CrossRefPubMed
  53. Aleksandrova K, Bamia C, Drogan D, et al. The association of coffee intake with liver cancer risk is mediated by biomarkers of inflammation and hepatocellular injury: data from the European Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2015; 102(6): 1498–1508.
    CrossRef
  54. Setiawan VW, Wilkens LR, Lu SC, et al. Association of coffee intake with reduced incidence of liver cancer and death from chronic liver disease in the US multiethnic cohort. Gastroenterology. 2015; 148(1): 118–25; quiz e15.
    CrossRefPubMed
  55. Li X, Sheng L, Liu L, et al. Statin and the risk of hepatocellular carcinoma in patients with hepatitis B virus or hepatitis C virus infection: a meta-analysis. BMC Gastroenterol. 2020; 20(1): 98.
    CrossRefPubMed
  56. Zhou YY, Zhu GQ, Liu T, et al. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci Rep. 2016; 6: 33743.
    CrossRefPubMed
  57. Wang S, Yu Y, Ryan PM, et al. Association of aspirin therapy with risk of hepatocellular carcinoma: A systematic review and dose-response analysis of cohort studies with 2.5 million participants. Pharmacol Res. 2020; 151: 104585.
    CrossRefPubMed
  58. Ramai D, Singh J, Lester J, et al. Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma. Aliment Pharmacol Ther. 2021; 53(9): 977–984.
    CrossRefPubMed
  59. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11(4): e1001624.
    CrossRefPubMed
  60. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018; 67(1): 358–380.
    CrossRefPubMed
  61. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014; 371(9): 796–797.
    CrossRefPubMed
  62. Thompson Coon J, Rogers G, Hewson P, et al. Surveillance of cirrhosis for hepatocellular carcinoma: systematic review and economic analysis. Health Technol Assess. 2007; 11(34): 1–206.
    CrossRefPubMed
  63. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009; 30(1): 37–47.
    CrossRefPubMed
  64. Fartoux L, Decaens T. Contribution of biomarkers and imaging in the management of hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2011; 35 Suppl 1: S21–S30.
    CrossRefPubMed
  65. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004; 130(7): 417–422.
    CrossRefPubMed
  66. Colli A, Nadarevic T, Miletic D, et al. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev. 2021; 4(4): CD 013346.
    CrossRef
  67. Nguyen MH, Garcia RT, Simpson PW, et al. Racial differences in effectiveness of alpha-fetoprotein for diagnosis of hepatocellular carcinoma in hepatitis C virus cirrhosis. Hepatology. 2002; 36(2): 410–417.
    CrossRefPubMed
  68. Bisceglie ADi, Sterling R, Chung R, et al. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: Results from the HALT-C Trial. J Hepatol. 2005; 43(3): 434–441.
    CrossRef
  69. Kim GA, Seock CH, Park JW, et al. Reappraisal of serum alpha-foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment. Liver Int. 2015; 35(1): 232–239.
    CrossRefPubMed
  70. Wong GLH, Chan HLY, Tse YK, et al. On-treatment alpha-fetoprotein is a specific tumor marker for hepatocellular carcinoma in patients with chronic hepatitis B receiving entecavir. Hepatology. 2014; 59(3): 986–995.
    CrossRefPubMed
  71. Bolondi L, Gaiani S, Celli N, et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology. 2005; 42(1): 27–34.
    CrossRefPubMed
  72. Forner A, Vilana R, Bianchi L, et al. Lack of arterial hypervascularity at contrast-enhanced ultrasound should not define the priority for diagnostic work-up of nodules <2 cm. J Hepatol. 2015; 62(1): 150–155.
    CrossRefPubMed
  73. Cucchetti A, Piscaglia F, Cescon M, et al. Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma. J Hepatol. 2013; 59(2): 300–307.
    CrossRefPubMed
  74. Roskams T. Anatomic pathology of hepatocellular carcinoma: impact on prognosis and response to therapy. Clin Liver Dis. 2011; 15(2): 245–59, vii.
    CrossRefPubMed
  75. American College of Radiology. Liver Imaging Reporting & Data System version 2018. https://www.acr.org/-/media/ACR/Files/RADS/LI-RADS/LI-RADS-2018-Core.pdf.
  76. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018; 391(10127): 1301–1314.
    CrossRef
  77. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1): 52–60.
    CrossRefPubMed
  78. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008; 47(1): 97–104.
    CrossRefPubMed
  79. Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology. 2008; 47(1): 82–89.
    CrossRefPubMed
  80. Kuang M, Xie XY, Huang C, et al. Long-term outcome of percutaneous ablation in very early-stage hepatocellular carcinoma. J Gastrointest Surg. 2011; 15(12): 2165–2171.
    CrossRefPubMed
  81. Khan AS, Hussain HK, Johnson TD, et al. Value of delayed hypointensity and delayed enhancing rim in magnetic resonance imaging diagnosis of small hepatocellular carcinoma in the cirrhotic liver. J Magn Reson Imaging. 2010; 32(2): 360–366.
    CrossRefPubMed
  82. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017; 11(4): 317–370.
    CrossRefPubMed
  83. Abd Alkhalik Basha M, Abd El Aziz El Sammak D, El Sammak AA. Diagnostic efficacy of the Liver Imaging-Reporting and Data System (LI-RADS) with CT imaging in categorising small nodules (10-20 mm) detected in the cirrhotic liver at screening ultrasound. Clin Radiol. 2017; 72(10): 901.e1–901.e11.
    CrossRefPubMed
  84. Choi SH, Byun JHo, Kim SoY, et al. Liver Imaging Reporting and Data System v2014 With Gadoxetate Disodium-Enhanced Magnetic Resonance Imaging: Validation of LI-RADS Category 4 and 5 Criteria. Invest Radiol. 2016; 51(8): 483–490.
    CrossRefPubMed
  85. Lee SiE, An C, Hwang SH, et al. Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease. Eur Radiol. 2018; 28(4): 1551–1559.
    CrossRefPubMed
  86. Liu W, Qin J, Guo R, et al. Accuracy of the diagnostic evaluation of hepatocellular carcinoma with LI-RADS. Acta Radiol. 2018; 59(2): 140–146.
    CrossRefPubMed
  87. Kim YY, An C, Kim S, et al. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI. Eur Radiol. 2018; 28(5): 2038–2046.
    CrossRefPubMed
  88. Kim MJ. Current limitations and potential breakthroughs for the early diagnosis of hepatocellular carcinoma. Gut Liver. 2011; 5(1): 15–21.
    CrossRefPubMed
  89. Rosenkrantz AB, Lee L, Matza BW, et al. Infiltrative hepatocellular carcinoma: comparison of MRI sequences for lesion conspicuity. Clin Radiol. 2012; 67(12): e105–e111.
    CrossRefPubMed
  90. Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging. 2003; 18(2): 189–195.
    CrossRefPubMed
  91. Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol. 2003; 39(6): 1076–1084.
    CrossRef
  92. Hanna RF, Miloushev VZ, Tang An, et al. Comparative 13-year meta-analysis of the sensitivity and positive predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY). 2016; 41(1): 71–90.
    CrossRefPubMed
  93. Chou R, Cuevas C, Fu R, et al. Imaging Techniques for the Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 162(10): 697–711.
    CrossRefPubMed
  94. Lee YJ, Lee JM, Lee JiS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging-a systematic review and meta-analysis. Radiology. 2015; 275(1): 97–109.
    CrossRefPubMed
  95. Aubé C, Oberti F, Lonjon J, et al. CHIC Group. EASL and AASLD recommendations for the diagnosis of HCC to the test of daily practice. Liver Int. 2017; 37(10): 1515–1525.
    CrossRefPubMed
  96. Piscaglia F, Wilson SR, Lyshchik A, et al. American College of Radiology Contrast Enhanced Ultrasound Liver Imaging Reporting and Data System (CEUS LI-RADS) for the diagnosis of Hepatocellular Carcinoma: a pictorial essay. Ultraschall Med. 2017; 38(3): 320–324.
    CrossRefPubMed
  97. Piscaglia F, Kudo M, Han KH, et al. Diagnosis of Hepatocellular Carcinoma with Non-Invasive Imaging: a Plea for Worldwide Adoption of Standard and Precise Terminology for Describing Enhancement Criteria. Ultraschall Med. 2017; 38(1): 9–11.
    CrossRefPubMed
  98. Mueller C, Waldburger N, Stampfl U, et al. Non-invasive diagnosis of hepatocellular carcinoma revisited. Gut. 2018; 67(5): 991–993.
    CrossRefPubMed
  99. Shin J, Lee S, Kim S, et al. Characteristics and Early Recurrence of Hepatocellular Carcinomas Categorized as LR‐M : Comparison with Those Categorized as LR ‐4 or 5. J Magn Reson Imaging. 2021.
    CrossRef
  100. An C, Park S, Chung YE, et al. Curative Resection of Single Primary Hepatic Malignancy: Liver Imaging Reporting and Data System Category LR-M Portends a Worse Prognosis. AJR Am J Roentgenol. 2017; 209(3): 576–583.
    CrossRefPubMed
  101. National Comprehensive Cancer Network. Hepatobiliary Cancers. Version 3.2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1438.
  102. Piscaglia F, Gianstefani A, Ravaioli M, et al. Bologna Liver Transplant Group. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl. 2010; 16(5): 658–667.
    CrossRefPubMed
  103. Sorrentino P, Tarantino L, D'Angelo S, et al. Validation of an extension of the international non-invasive criteria for the diagnosis of hepatocellular carcinoma to the characterization of macroscopic portal vein thrombosis. J Gastroenterol Hepatol. 2011; 26(4): 669–677.
    CrossRefPubMed
  104. Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology. 2010; 254(1): 154–162.
    CrossRefPubMed
  105. Voizard N, Cerny M, Assad A, et al. Assessment of hepatocellular carcinoma treatment response with LI-RADS: a pictorial review. Insights Imaging. 2019; 10(1): 121.
    CrossRefPubMed
  106. Yopp AC, Mansour JC, Beg MS, et al. Establishment of a multidisciplinary hepatocellular carcinoma clinic is associated with improved clinical outcome. Ann Surg Oncol. 2014; 21(4): 1287–1295.
    CrossRefPubMed
  107. Sinn DH, Choi GS, Park HC, et al. Multidisciplinary approach is associated with improved survival of hepatocellular carcinoma patients. PLoS One. 2019; 14(1): e0210730.
    CrossRefPubMed
  108. Li X, Chen Q, Bi X, et al. Effects of multidisciplinary team on the outcomes of colorectal cancer patients with liver metastases. Ann Palliat Med. 2020; 9(5): 2741–2748.
    CrossRefPubMed
  109. Marszałek A, Langfort R, Ryś J. Patomorfologia: standardy i przykłady dobrej praktyki oraz elementy diagnostyki różnicowej. Wytyczne dla zakładów/pracowni patomorfologii. 2020. http://pol-pat.pl/index.php/2020/08/29/standardy-i-wytyczne-w-patomorfologii/.
  110. Paradis V, Fukuyama M, Park YN, Schrimacher P. Tumours of the liver and intrahepatic bile ducts. W WHO classification of tumours. 5th edition. Digestive System Tumours. Edited by the WHO Classification of Tumours Editorial Board, Lyon 2019: 216–239.
  111. Sparchez Z, Mocan T. Contemporary role of liver biopsy in hepatocellular carcinoma. World J Hepatol. 2018; 10(7): 452–461.
    CrossRefPubMed
  112. Di Tommaso L, Spadaccini M, Donadon M, et al. Role of liver biopsy in hepatocellular carcinoma. World J Gastroenterol. 2019; 25(40): 6041–6052.
    CrossRefPubMed
  113. Russo FP, Imondi A, Lynch EN, et al. When and how should we perform a biopsy for HCC in patients with liver cirrhosis in 2018? A review. Dig Liver Dis. 2018; 50(7): 640–646.
    CrossRefPubMed
  114. The Cancer Genome Atlas Research Network. Cell. 2017; 169: 1327–1341.
  115. CCN Guidelines Version 3.2021 Hepatocellular carcinoma. www.nccn.org.
  116. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006; 44(1): 217–231.
    CrossRefPubMed
  117. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985; 56(4): 918–928, doi: 10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e.
  118. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28(3): 751–755.
    CrossRefPubMed
  119. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999; 29(1): 62–67.
    CrossRefPubMed
  120. Villa E, Moles A, Ferretti I, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000; 32(2): 233–238.
    CrossRefPubMed
  121. Cabibbo G, Enea M, Attanasio M, et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010; 51(4): 1274–1283.
    CrossRefPubMed
  122. Amin MB, Edge SB. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 8th Edition. Springer, New York 2017.
  123. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology. 1998; 27(6): 1572–1577.
    CrossRefPubMed
  124. Chan ACY, Fan ST, Poon RTP, et al. Evaluation of the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) staging system for patients undergoing curative resection of hepatocellular carcinoma: implications for the development of a refined staging system. HPB (Oxford). 2013; 15(6): 439–448.
    CrossRefPubMed
  125. Chevret S, Trinchet JC, Mathieu D, et al. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. J Hepatol. 1999; 31(1): 133–141.
    CrossRef
  126. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19(3): 329–338.
    CrossRefPubMed
  127. Leung TWT, Tang AMY, Zee B, et al. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer. 2002; 94(6): 1760–1769.
    CrossRefPubMed
  128. Yau T, Tang VYF, Yao TJ, et al. Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014; 146(7): 1691–700.e3.
    CrossRefPubMed
  129. Kitai S, Kudo M, Minami Y, et al. Validation of a new prognostic staging system for hepatocellular carcinoma: a comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology. 2008; 75 Suppl 1: 83–90.
    CrossRefPubMed
  130. Sohn JHo, Duran R, Zhao Y, et al. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. Clin Gastroenterol Hepatol. 2017; 15(5): 746–755.e4.
    CrossRefPubMed
  131. Sherman M. Staging for hepatocellular carcinoma: complex and confusing. Gastroenterology. 2014; 146(7): 1599–1602.
    CrossRefPubMed
  132. Marrero JA, Fontana RJ, Barrat A, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology. 2005; 41(4): 707–716.
    CrossRefPubMed
  133. Cillo U, Bassanello M, Vitale A, et al. The critical issue of hepatocellular carcinoma prognostic classification: which is the best tool available? J Hepatol. 2004; 40(1): 124–131.
    CrossRefPubMed
  134. Guglielmi A, Ruzzenente A, Pachera S, et al. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response. Am J Gastroenterol. 2008; 103(3): 597–604.
    CrossRefPubMed
  135. Vitale A, Saracino E, Boccagni P, et al. Validation of the BCLC prognostic system in surgical hepatocellular cancer patients. Transplant Proc. 2009; 41(4): 1260–1263.
    CrossRefPubMed
  136. Llovet J, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 362(9399): 1907–1917.
    CrossRefPubMed
  137. Llovet JM, Di Bisceglie AM, Bruix J, et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008; 100(10): 698–711.
    CrossRefPubMed
  138. Forner A, Llovet J, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379(9822): 1245–1255.
    CrossRefPubMed
  139. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst. 2009; 101(21): 1446–1452.
    CrossRefPubMed
  140. Pinyol R, Montal R, Bassaganyas L, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut. 2019; 68(6): 1065–1075.
    CrossRefPubMed
  141. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015; 33(6): 550–558.
    CrossRefPubMed
  142. Pinato DJ, Sharma R, Allara E, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017; 66(2): 338–346.
    CrossRefPubMed
  143. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003; 38(2): 200–207.
    CrossRefPubMed
  144. Ikai I, Arii S, Kojiro M, et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer. 2004; 101(4): 796–802.
    CrossRefPubMed
  145. Vibert E, Azoulay D, Hoti E, et al. Progression of alphafetoprotein before liver transplantation for hepatocellular carcinoma in cirrhotic patients: a critical factor. Am J Transplant. 2010; 10(1): 129–137.
    CrossRefPubMed
  146. Merani S, Majno P, Kneteman NM, et al. The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma. J Hepatol. 2011; 55(4): 814–819.
    CrossRefPubMed
  147. Toso C, Dupuis-Lozeron E, Majno P, et al. A model for dropout assessment of candidates with or without hepatocellular carcinoma on a common liver transplant waiting list. Hepatology. 2012; 56(1): 149–156.
    CrossRefPubMed
  148. Duvoux C, Roudot-Thoraval F, Decaens T, et al. Liver Transplantation French Study Group. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology. 2012; 143(4): 986–94.e3; quiz e14.
    CrossRefPubMed
  149. Llovet JM, Peña CEA, Lathia CD, et al. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18(8): 2290–2300.
    CrossRefPubMed
  150. Kokudo N, Hasegawa K, Akahane M, et al. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines). Hepatol Res. 2015; 45(2).
    CrossRefPubMed
  151. Roskams T, Kojiro M. Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis. Semin Liver Dis. 2010; 30(1): 17–25.
    CrossRefPubMed
  152. Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013; 58(4): 724–729.
    CrossRefPubMed
  153. Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology. 2013; 57(4): 1426–1435.
    CrossRefPubMed
  154. Takayasu K, Arii S, Sakamoto M, et al. Liver Cancer Study Group of Japan. Impact of resection and ablation for single hypovascular hepatocellular carcinoma ≤2 cm analysed with propensity score weighting. Liver Int. 2018; 38(3): 484–493.
    CrossRefPubMed
  155. Cho YKu, Kim JK, Kim WT, et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010; 51(4): 1284–1290.
    CrossRefPubMed
  156. Sala M, Fuster J, Llovet JM, et al. Barcelona Clinic Liver Cancer (BCLC) Group. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl. 2004; 10(10): 1294–1300.
    CrossRefPubMed
  157. Fuks D, Dokmak S, Paradis V, et al. Benefit of initial resection of hepatocellular carcinoma followed by transplantation in case of recurrence: an intention-to-treat analysis. Hepatology. 2012; 55(1): 132–140.
    CrossRefPubMed
  158. Lope Cde, Tremosini S, Forner A, et al. Management of HCC. Journal of Hepatology. 2012; 56: S75–S87.
    CrossRef
  159. Forner A, Reig ME, de Lope CR, et al. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1): 61–74.
    CrossRefPubMed
  160. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30(6): 1434–1440.
    CrossRefPubMed
  161. Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. Gastroenterology. 2008; 134(7): 1908–1916.
    CrossRefPubMed
  162. Berzigotti A, Reig M, Abraldes JG, et al. Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology. 2015; 61(2): 526–536.
    CrossRefPubMed
  163. N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50(5): 1475–1483.
    CrossRefPubMed
  164. Lencioni R, Cioni D, Crocetti L, et al. Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005; 234(3): 961–967.
    CrossRefPubMed
  165. Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a first-line treatment: long-term results and prognostic factors in a large single-institution series. Eur Radiol. 2007; 17(3): 684–692.
    CrossRefPubMed
  166. Sala M, Llovet JM, Vilana R, et al. Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004; 40(6): 1352–1360.
    CrossRefPubMed
  167. Al-Shamsi HO, Abdel-Wahab R, Hassan MM, et al. Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States. Oncology. 2017; 93(4): 233–242.
    CrossRefPubMed
  168. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2): 429–442.
    CrossRefPubMed
  169. Llovet J, Real M, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 359(9319): 1734–1739.
    CrossRefPubMed
  170. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 35(5): 1164–1171.
    CrossRefPubMed
  171. Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012; 56(4): 886–892.
    CrossRefPubMed
  172. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56(6): 1330–1335.
    CrossRefPubMed
  173. Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012; 35(5): 1119–1128.
    CrossRefPubMed
  174. Bolondi L, Burroughs A, Dufour JF, et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis. 2012; 32(4): 348–359.
    CrossRefPubMed
  175. Hucke F, Pinter M, Graziadei I, et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. J Hepatol. 2014; 61(6): 1287–1296.
    CrossRefPubMed
  176. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4): 908–943.
    CrossRefPubMed
  177. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53(3): 1020–1022.
    CrossRefPubMed
  178. Tsochatzis E, Bosch J, Burroughs A. Liver cirrhosis. Lancet. 2014; 383(9930): 1749–1761.
    CrossRefPubMed
  179. Llovet JM, Ricci S, Mazzaferro V, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4): 378–390.
    CrossRefPubMed
  180. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10(1): 25–34.
    CrossRefPubMed
  181. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389(10064): 56–66.
    CrossRefPubMed
  182. Kudo M, Finn R, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018; 391(10126): 1163–1173.
    CrossRefPubMed
  183. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med. 2018; 379(1): 54–63.
    CrossRefPubMed
  184. Lencioni R, Kudo M, Ye SL, et al. GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis. Int J Clin Pract. 2014; 68(5): 609–617.
    CrossRefPubMed
  185. Mazzaferro V, Sposito C, Zhou J, et al. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma. Gastroenterology. 2018; 154(1): 128–139.
    CrossRefPubMed
  186. Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol. 2020; 21(7): 947–956.
    CrossRefPubMed
  187. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011; 37(3): 212–220.
    CrossRefPubMed
  188. Forner A, Gilabert M, Bruix J, et al. Treatment of intermediate-stage hepatocellular carcinoma. Nat Rev Clin Oncol. 2014; 11(9): 525–535.
    CrossRefPubMed
  189. Llovet JM. Hepatocellular carcinoma. Nature Reviews. Disease Primers 2016.
  190. Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017; 14(4): 203–217.
    CrossRefPubMed
  191. Krawczyk M, Zieniewicz K. Pierwotny rak wątroby. In: Krawczyk M. ed. Chirurgia dróg żółciowych i wątroby, t. 2. PZWL 2013.
  192. Vogel A, Cervantes A, Chau I. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Committee e-Update – Hepatocellular Carcinoma Treatment Recommendations, ESMO 2020.
  193. Benson AB, et al. D’Angelica M, Abbott DE Hepatobiliary Cancers, Version 2.202. NCCN Clinical Practice Guidelines in Oncology. JNCCN. 2021; 19(5).
  194. Krawczyk M. Rak wątrobowokomórkowy. PZWL 2015.
  195. Zieniewicz K. Rak wątrobowokomórkowy. In: Jeziorski A, Rutkowski P, Wysocki W. ed. Chirurgia onkologiczna, t. 3. PZWL 2019.
  196. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 334(11): 693–699.
    CrossRefPubMed
  197. Clavien PA, Lesurtel M, Bossuyt P, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol. 2012; 13(1): e11–e22.
    CrossRef
  198. Yao F. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology. 2001; 33(6): 1394–1403.
    CrossRef
  199. Mazzaferro V, Llovet J, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009; 10(1): 35–43.
    CrossRef
  200. Grąt M, Wronka KM, Stypułkowski J, et al. The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer. Ann Surg Oncol. 2017; 24(2): 526–534.
    CrossRefPubMed
  201. Sapisochin G, Goldaracena N, Laurence JM, et al. The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study. Hepatology. 2016; 64(6): 2077–2088.
    CrossRefPubMed
  202. Toso C, Asthana S, Bigam DL, et al. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology. 2009; 49(3): 832–838.
    CrossRefPubMed
  203. Lai Q, Nicolini D, Inostroza Nunez M, et al. A Novel Prognostic Index in Patients With Hepatocellular Cancer Waiting for Liver Transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) Score. Ann Surg. 2016; 264(5): 787–796.
    CrossRefPubMed
  204. Ye YF, Wang W, Wang T, et al. Role of [F] fludeoxyglucose positron emission tomography in the selection of liver transplantation candidates in patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2017; 16(3): 257–263.
    CrossRefPubMed
  205. Grąt M, Kornasiewicz O, Lewandowski Z, et al. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence. World J Surg. 2014; 38(10): 2698–2707.
    CrossRefPubMed
  206. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis. 2007; 25(4): 310–312.
    CrossRefPubMed
  207. Grąt M, Krasnodębski M, Patkowski W, et al. Relevance of Pre-Transplant α-fetoprotein Dynamics in Liver Transplantation for Hepatocellular Cancer. Ann Transplant. 2016; 21: 115–124.
    CrossRefPubMed
  208. Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology. 2018; 67(1): 381–400.
    CrossRefPubMed
  209. Mangus RS, Fridell JA, Vianna RM, et al. Use of the piggyback hepatectomy technique in liver transplant recipients with hepatocellular carcinoma. Transplantation. 2008; 85(10): 1496–1499.
    CrossRefPubMed
  210. Grąt M, Kornasiewicz O, Lewandowski Z, et al. The impact of surgical technique on the results of liver transplantation in patients with hepatocellular carcinoma. Ann Transplant. 2013; 18: 448–459.
    CrossRefPubMed
  211. Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation. 2016; 100(1): 116–125.
    CrossRefPubMed
  212. Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl. 2013; 19(1): 3–26.
    CrossRefPubMed
  213. Sapisochin G, Goldaracena N, Astete S, et al. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series. Ann Surg Oncol. 2015; 22(7): 2286–2294.
    CrossRefPubMed
  214. Grąt M. Transplantacja wątroby w leczeniu chorych z HCC. In: Jeziorski A, Rutkowski P, Wysocki W. ed. Chirurgia onkologiczna, t. 3. PZWL 2019.
  215. Krawczyk M, Wasilewicz MP, Hartleb M, et al. Rozpoznawanie i leczenie raka wątrobowokomórkowego – rekomendacje Sekcji Hepatologicznej Polskiego Towarzystwa Gastroenterologii. Gastroenterologia Kliniczna. 2015; 7(3): 65–89.
  216. Agarwal PD, Phillips P, Hillman L, et al. Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival. J Clin Gastroenterol. 2017; 51(9): 845–849.
    CrossRefPubMed
  217. NCCN (2021) Hepatobiliary cancers (Hepatocelluar) v. 2.2021. NCCN.
  218. Roayaie S, Jibara G, Tabrizian P, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015; 62(2): 440–451.
    CrossRefPubMed
  219. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021; 7(1): 6.
    CrossRefPubMed
  220. Doyle A, Gorgen A, Muaddi H, et al. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients. J Hepatol. 2019; 70(5): 866–873.
    CrossRefPubMed
  221. Xu Y, Shen Q, Wang N, et al. Microwave ablation is as effective as radiofrequency ablation for very-early-stage hepatocellular carcinoma. Chin J Cancer. 2017; 36(1): 14.
    CrossRefPubMed
  222. Sasaki A, Kai S, Iwashita Y, et al. Microsatellite distribution and indication for locoregional therapy in small hepatocellular carcinoma. Cancer. 2005; 103(2): 299–306.
    CrossRefPubMed
  223. Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017; 104(13): 1775–1784.
    CrossRefPubMed
  224. Kudo M, Hasegawa K, Kawaguchi Y, et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival. J Clin Oncol. 2021; 39(15_suppl): 4093–4093.
    CrossRef
  225. Izumi N, Hasegawa K, Nishioka Y, et al. A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial). J Clin Oncol. 2019; 37(15_suppl): 4002–4002.
    CrossRef
  226. Zhang M, Ma H, Zhang J, et al. Comparison of microwave ablation and hepatic resection for hepatocellular carcinoma: a meta-analysis. Onco Targets Ther. 2017; 10: 4829–4839.
    CrossRefPubMed
  227. Lee MW, Kang D, Lim HK, et al. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol. 2020; 30(4): 2391–2400.
    CrossRefPubMed
  228. Bai XM, Cui M, Yang W, et al. The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC. Radiology. 2021; 300(2): 458–469.
    CrossRefPubMed
  229. Xia Y, Li J, Liu G, et al. Long-term Effects of Repeat Hepatectomy vs Percutaneous Radiofrequency Ablation Among Patients With Recurrent Hepatocellular Carcinoma: A Randomized Clinical Trial. JAMA Oncol. 2020; 6(2): 255–263.
    CrossRefPubMed
  230. Cho YKu, Kim JK, Kim MiY, et al. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009; 49(2): 453–459.
    CrossRefPubMed
  231. Germani G, Pleguezuelo M, Gurusamy K, et al. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic acid injection for hepatocelullar carcinoma: a meta-analysis. J Hepatol. 2010; 52(3): 380–388.
    CrossRefPubMed
  232. Galle P, Forner A, Llovet J, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018; 69(1): 182–236.
    CrossRef
  233. Glassberg MB, Ghosh S, Clymer JW, et al. Microwave ablation compared with radiofrequency ablation for treatment of hepatocellular carcinoma and liver metastases: a systematic review and meta-analysis. Onco Targets Ther. 2019; 12: 6407–6438.
    CrossRefPubMed
  234. An C, Li WZ, Huang ZM, et al. Small single perivascular hepatocellular carcinoma: comparisons of radiofrequency ablation and microwave ablation by using propensity score analysis. Eur Radiol. 2021; 31(7): 4764–4773.
    CrossRefPubMed
  235. Feng Y, Wang Le, Lv H, et al. Microwave ablation versus radiofrequency ablation for perivascular hepatocellular carcinoma: a propensity score analysis. HPB (Oxford). 2021; 23(4): 512–519.
    CrossRefPubMed
  236. Della Corte A, Ratti F, Monfardini L, et al. Comparison between percutaneous and laparoscopic microwave ablation of hepatocellular carcinoma. Int J Hyperthermia. 2020; 37(1): 542–548.
    CrossRefPubMed
  237. Wong J, Lee KF, Yu SCH, et al. Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results. HPB (Oxford). 2013; 15(8): 595–601.
    CrossRefPubMed
  238. Khan MR, Poon RTP, Ng KK, et al. Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma. Arch Surg. 2007; 142(12): 1136–43; discussion 1143.
    CrossRefPubMed
  239. Crocetti L, de Baére T, Pereira PL, et al. CIRSE Standards of Practice on Thermal Ablation of Liver Tumours. Cardiovasc Intervent Radiol. 2020; 43(7): 951–962.
    CrossRefPubMed
  240. Maeda M, Saeki I, Sakaida I, et al. Complications after Radiofrequency Ablation for Hepatocellular Carcinoma: A Multicenter Study Involving 9,411 Japanese Patients. Liver Cancer. 2020; 9(1): 50–62.
    CrossRefPubMed
  241. Chu HHo, Kim JH, Yoon HK, et al. Chemoembolization Combined with Radiofrequency Ablation for Medium-Sized Hepatocellular Carcinoma: A Propensity-Score Analysis. J Vasc Interv Radiol. 2019; 30(10): 1533–1543.
    CrossRefPubMed
  242. Jiang C, Cheng G, Liao M, et al. Individual or combined transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma: a time-to-event meta-analysis. World J Surg Oncol. 2021; 19(1): 81.
    CrossRefPubMed
  243. Liu D, Liu M, Su L, et al. Transarterial Chemoembolization Followed by Radiofrequency Ablation for Hepatocellular Carcinoma: Impact of the Time Interval between the Two Treatments on Outcome. J Vasc Interv Radiol. 2019; 30(12): 1879–1886.
    CrossRefPubMed
  244. Bauschke A, Altendorf-Hofmann A, Ardelt M, et al. Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis. J Cancer Res Clin Oncol. 2020; 146(7): 1819–1827.
    CrossRefPubMed
  245. Cammà C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002; 224(1): 47–54.
    CrossRefPubMed
  246. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003; 37(2): 429–442.
    CrossRefPubMed
  247. Biederman DM, Titano JJ, Korff RA, et al. Radiation Segmentectomy versus Selective Chemoembolization in the Treatment of Early-Stage Hepatocellular Carcinoma. J Vasc Interv Radiol. 2018; 29(1): 30–37.e2.
    CrossRefPubMed
  248. Kang YJ, Lee BC, Kim JK, et al. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma. Cardiovasc Intervent Radiol. 2020; 43(1): 55–64.
    CrossRefPubMed
  249. Golfieri R, Giampalma E, Renzulli M, et al. PRECISION ITALIA STUDY GROUP. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014; 111(2): 255–264.
    CrossRefPubMed
  250. Lammer J, Malagari K, Vogl T, et al. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010; 33(1): 41–52.
    CrossRefPubMed
  251. Bolondi L, Cillo U, Colombo M, et al. Italian Association for the Study of the Liver (AISF), AISF Expert Panel, AISF Coordinating Committee. Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Dig Liver Dis. 2013; 45(9): 712–723.
    CrossRefPubMed
  252. Kim JH, Shim JuH, Lee HC, et al. New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. Liver Int. 2017; 37(12): 1861–1868.
    CrossRefPubMed
  253. Lencioni R, de Baere T, Soulen MC, et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016; 64(1): 106–116.
    CrossRefPubMed
  254. Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig Liver Dis. 2016; 48(6): 571–577.
    CrossRefPubMed
  255. Bargellini I, Lorenzoni V, Lorenzoni G, et al. Duration of response after DEB-TACE compared to lipiodol-TACE in HCC-naïve patients: a propensity score matching analysis. Eur Radiol. 2021 [Epub ahead of print].
    CrossRefPubMed
  256. Zhang ZS, Li HZ, Ma C, et al. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety. BMC Cancer. 2019; 19(1): 1162.
    CrossRefPubMed
  257. Ikeda M, Inaba Y, Tanaka T, et al. A prospective randomized controlled trial of selective transarterial chemoembolization using drug-eluting beads loaded with epirubicin versus selective conventional transarterial chemoembolization using epirubicin-lipiodol for hepatocellular carcinoma: The JIVROSG-1302 PRESIDENT study. J Clin Oncol. 2020; 38(15_suppl): 4518–4518.
    CrossRef
  258. Mezhir JJ, Fong Y, Fleischer D, et al. Pyogenic abscess after hepatic artery embolization: a rare but potentially lethal complication. J Vasc Interv Radiol. 2011; 22(2): 177–182.
    CrossRefPubMed
  259. Chang L, Wang W, Jiang N, et al. Dexamethasone prevents TACE-induced adverse events: A meta-analysis. Medicine (Baltimore). 2020; 99(47): e23191.
    CrossRefPubMed
  260. Chen S, Peng Z, Zhang Y, et al. Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat? Radiology. 2021; 298(3): 680–692.
    CrossRefPubMed
  261. Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2017; 2(8): 565–575.
    CrossRefPubMed
  262. Garin E, Palard X, Rolland Y. Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design. Cancers (Basel). 2020; 12(6).
    CrossRefPubMed
  263. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011; 140(2): 497–507.e2.
    CrossRefPubMed
  264. Salem R, Gordon AC, Mouli S, et al. Y90 Radioembolization Significantly Prolongs Time to Progression Compared With Chemoembolization in Patients With Hepatocellular Carcinoma. Gastroenterology. 2016; 151(6): 1155–1163.e2.
    CrossRefPubMed
  265. Vilgrain V, Pereira H, Assenat E, et al. SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017; 18(12): 1624–1636.
    CrossRefPubMed
  266. Chow PKH, Gandhi M, Tan SB, et al. Asia-Pacific Hepatocellular Carcinoma Trials Group. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J Clin Oncol. 2018; 36(19): 1913–1921.
    CrossRefPubMed
  267. Hermann AL, Dieudonné A, Ronot M, et al. SARAH Trial Group. Relationship of Tumor Radiation-absorbed Dose to Survival and Response in Hepatocellular Carcinoma Treated with Transarterial Radioembolization with Y in the SARAH Study. Radiology. 2020; 296(3): 673–684.
    CrossRefPubMed
  268. Somma F, Stoia V, Serra N, et al. Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival. PLoS One. 2019; 14(5): e0216935.
    CrossRefPubMed
  269. Salem R, Gilbertsen M, Butt Z, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013; 11(10): 1358–1365.e1.
    CrossRefPubMed
  270. Bruix J, Takayama T, Mazzaferro V, et al. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015; 16(13): 1344–1354.
    CrossRefPubMed
  271. Zhang X, Yang XR, Huang XW, et al. Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 2012; 11(5): 458–466.
    CrossRef
  272. McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer. 2018; 105: 1–9.
    CrossRefPubMed
  273. Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019; 5(11): 1582–1588.
    CrossRefPubMed
  274. Cheng AL, Kang YK, Lin DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol. 2013; 31(32): 4067–4075.
    CrossRefPubMed
  275. Fizazi K, Maillard A, Penel N, et al. A phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04). Ann Oncol. 2019; 30(Suppl. 5): v851.
    CrossRef
  276. Finn RS, Qin S, Ikeda M, et al. IMbrave150 Investigators. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020; 382(20): 1894–1905.
    CrossRefPubMed
  277. Zhu AX, Kang YK, Yen CJ, et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2): 282–296.
    CrossRefPubMed
  278. Finn RS, Ryoo BY, Merle P, et al. KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. J Clin Oncol. 2020; 38(3): 193–202.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl